This site is intended for healthcare professionals
News

FDA approves Anjeso to treat moderate to severe pain.- Baudax Bio

Read time: 1 mins
Published:23rd Feb 2020
Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. Anjeso is approved for the management of moderate to severe pain and will be administered as a once-a-day intravenous (IV) bolus push. Anjeso is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing. The active ingredient meloxicam is a long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis.
Condition: Pain:Post Surgical
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.